Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open Label Single-Arm, Phase 2 Study of Zandelisib (ME-401) in Subjects With Follicular Lymphoma and Marginal Zone Lymphoma After Failure of Two or More Prior Systemic Therapies (The TIDAL Study)

NCT03768505 is registered in ClinicalTrials.gov with MEI Pharma, Inc. as lead sponsor.

NCT NCT03768505
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03768505 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open Label Single-Arm, Phase 2 Study of Zandelisib (ME-401) in Subjects With Follicular Lymphoma and Marginal Zone Lymphoma After Failure of Two or More Prior Systemic Therapies (The TIDAL Study)
Lead sponsor
MEI Pharma, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
June 25, 2019
Completion date
March 24, 2023
Enrollment
169 (actual)
Sites
115

Conditions

As the registry lists them; a condition with its own page is linked.

follicular lymphoma (fl), marginal zone lymphoma, non hodgkin lymphoma